This article was originally published in The Rose Sheet
The National Advertising Division of the Council of Better Business Bureaus recommends Modern Health Labs modify or discontinue ad claims in an infomercial and Web site for its Scalp Med hair re-growth product because the five statements reviewed in the case were either not supported by evidence or could confuse customers, agency reports. NAD further recommends the advertiser disclose in ads that the principal hair growth ingredient in its product is FDA-approved minoxidil. The case was brought to NAD's attention by competitor Global Vision Products...
You may also be interested in...
The Association for Accessible Medicines has appointed former Biotechnology Innovation Organization representative Joanne Duncan as its new chief operating officer. Meanwhile, Coherus has names the new chair of its scientific advisory board, while women’s health specialist Theramex has added to its board of directors.
Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.